Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH St. John's wort trial

This article was originally published in The Tan Sheet

Executive Summary

NIH clinical trial studying St. John's wort's efficacy in treating depression has enrolled about one-fourth of the expected 330 patients. The study, led by principle investigator Jonathan Davidson, MD, Duke University, is being funded by NIH's National Center for Complementary & Alternative Medicine, National Institute of Mental Health and Office of Dietary Supplements. Recruitment was delayed due to a problem with Duke's Review Board research review procedures ("The Tan Sheet" May 17, In Brief)

You may also be interested in...



Complementary Therapies Availability Poses Threat To Controlled Liver Trials

Widespread use of alternative medicines for chronic liver disease will complicate randomized, controlled trials of those substances, former NIH Office of Alternative Medicine Director Wayne Jonas, MD, told a National Institutes of Health workshop on "Complementary and Alternative Medicine in Chronic Liver Disease" Aug. 23.

Complementary Therapies Availability Poses Threat To Controlled Liver Trials

Widespread use of alternative medicines for chronic liver disease will complicate randomized, controlled trials of those substances, former NIH Office of Alternative Medicine Director Wayne Jonas, MD, told a National Institutes of Health workshop on "Complementary and Alternative Medicine in Chronic Liver Disease" Aug. 23.

Complementary Therapies Availability Poses Threat To Controlled Liver Trials

Widespread use of alternative medicines for chronic liver disease will complicate randomized, controlled trials of those substances, former NIH Office of Alternative Medicine Director Wayne Jonas, MD, told a National Institutes of Health workshop on "Complementary and Alternative Medicine in Chronic Liver Disease" Aug. 23.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel